Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 7/20 | 0.67 |
| ▸ | RAB9A | P51151 | 6/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.67 |
| ▸ | MAPT | P10636 | 6/20 | 0.67 |
| ▸ | NPC1 | O15118 | 5/20 | 0.67 |
| ▸ | MEN1 | O00255 | 5/20 | 0.67 |
| ▸ | LMNA | P02545 | 2/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.67 |
| ▸ | HPGD | P15428 | 3/20 | 0.60 |
| ▸ | ATM | Q13315 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | PPIA | P62937 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.56 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2312502 | 0.87 | KMT2A (0.75) | KMT2ARAB9ASMN1; SMN2MAPTNPC1 | |
| SCHEMBL2312499 | 0.87 | KMT2A (0.75) | KMT2ARAB9ASMN1; SMN2MAPTNPC1 | |
| SCHEMBL11326938 | 0.87 | KMT2A (0.85) | KMT2ARAB9ASMN1; SMN2MAPTNPC1 | |
| SCHEMBL27684440 | 0.86 | KMT2A (0.61) | KMT2ARAB9ASMN1; SMN2MAPTNPC1 | |
| SCHEMBL14662373 | 0.86 | PPIA (0.66) | KMT2ARAB9ASMN1; SMN2MAPTNPC1 | |
| SCHEMBL7600834 | 0.85 | ALDH1A1 (0.72) | KMT2ARAB9ASMN1; SMN2MAPTNPC1 | |
| SCHEMBL30483195 | 0.85 | ALDH1A1 (0.72) | KMT2ARAB9ASMN1; SMN2MAPTNPC1 | |
| Nitric Acid SCHEMBL3858285 | 0.83 | KMT2A (0.58) | KMT2ARAB9ASMN1; SMN2MAPTNPC1 | |
| SCHEMBL10889357 | 0.83 | KMT2A (0.65) | KMT2ARAB9ASMN1; SMN2MAPTNPC1 | |
| SCHEMBL27761089 | 0.82 | MAPK1 (0.54) | KMT2ARAB9ASMN1; SMN2MAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1656237-A | Antiviral inhibition of capsid proteins | UNIV MARYLAND (US) | 2005-08-17 | — | — | CN | claimed |
| CN-102264720-A | Isoindoline compounds for the treatment of cancer | — | 2011-11-30 | — | — | CN | disclosed |
| US-7361459-B2 | Antiviral inhibition of capsid proteins | UNIVERSITY OF MARYLAND, BALTIMORE COUNTY (US) | 2008-04-22 | — | — | US | disclosed |
| US-20070010671-A1 | Novel quinazoline derivatives and methods of treatment related to the use thereof | ARENA PHARMACEUTICALS, INC. | 2007-01-11 | — | — | US | disclosed |
| CN-1656237-A | Antiviral inhibition of capsid proteins | UNIV MARYLAND (US) | 2005-08-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010671-A1 | Novel quinazoline derivatives and methods of treatment related to the use thereof | MCHR1, GPR119, MCHR2 | KMT2A 792/4885RAB9A 902/4885SMN1; SMN2 1509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.